Insulin-like Growth Factor 1 Therapy for Type B Insulin Resistance
Authors: Tsutomu Hirano
Journal: Annals of Internal Medicine (1997)

Letters1 August 1997Insulin-like Growth Factor 1 Therapy for Type B Insulin ResistanceTsutomu Hirano, MD and Mitsura Adachi, MDTsutomu Hirano, MDShowa University School of Medicine; Tokyo 142, JapanSearch for more papers by this author and Mitsura Adachi, MDShowa University School of Medicine; Tokyo 142, JapanSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-127-3-199708010-00024 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The type B insulin-resistance syndrome is characterized by the presence of anti-insulin receptor antibodies that cause severe insulin resistance [1, 2]. A 44-year-old, nonobese woman with Hashimoto thyroiditis and the Sjogren syndrome demonstrated severe insulin resistance and acanthosis nigricans. Plasma glucose and insulin levels during oral glucose tolerance testing were 7.3 to 22.1 mmol/L and 4264 to 10 986 pmol/L, respectively. Anti-insulin receptor antibodies were detected in serum, but results of tests for anti-insulin antibody were negative. When oral prednisolone was administered at a starting dose of 40 mg, severe hyperglycemia immediately developed. Because massive insulin injections ...References1. Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM, et al. The syndromes of insulin resistance and acanthosis nigricans. N Engl J Med. 1976; 294:739-45. Google Scholar2. Tsokos GC, Gorden P, Antonovych T, Wilson CB, Balow JE. Lupus nephritis and other autoimmune features in patients with diabetes mellitus due to autoantibody to insulin receptors. Ann Intern Med. 1985; 102:176-81. Google Scholar3. Weinstein SP, Paquin T, Pritsker A, Harber R. Glucocorticoid-induced insulin resistance: dexamethasone inhibits the activation of glucose transport in rat skeletal muscle by both insulin- and non-insulin-related stimuli. Diabetes. 1995; 44:441-5. Google Scholar4. Kuzuya H, Matusuura N, Sakamoto M, Makino H, Sakamoto Y, Kadowaki T, et al. Trial of insulin-like growth factor 1 therapy for patients with extreme insulin resistance syndromes. Diabetes. 1993; 42:696-705. Google Scholar5. Tappy L, Fujita-Yamaguchi Y, Lebon TR, Boden G. Antibodies to insulin-like growth factor 1 receptors in diabetes and other disorders. Diabetes. 1988; 37:1708-1914. Google Scholar Author, Article, and Disclosure InformationAuthors: Tsutomu Hirano, MD; Mitsura Adachi, MDAffiliations: Showa University School of Medicine; Tokyo 142, Japan PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCase report: Successful combination therapy with double-filtration plasmapheresis and rituximab under the condition of the use of a sensor-augmented pump for type B insulin resistance syndromeClinical characteristics of insulin resistance syndromes: A nationwide survey in JapanType B insulin resistance syndromeA Case of Type B Insulin-resistance Syndrome Ameliorated with Immune-suppression TherapiesType B insulin resistance syndrome with fasting hypoglycemia and postprandial hyperglycemiaType B Insulin Resistance Syndrome Associated with Systemic Lupus ErythematosusClinical efficacy of insulin-like growth factor-1 in a patient with autoantibodies to insulin receptors: a case report 1 August 1997Volume 127, Issue 3Page: 245-246KeywordsAntibodiesBlood plasmaGlucoseHyperglycemiaInsulinInsulin like growth factor 1Insulin resistanceInsulin-like growth factorsSubcutaneous injectionsThyroid ePublished: 15 August 2000 Issue Published: 1 August 1997 Copyright & PermissionsCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...